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Heredi tary hemochromatosis (HH) is the most common metabolic genetic disorder and affects approximately 1 in 180 members of the white population. 1, 2 We have previously reported that the aerobic exercise capacity of cardiac asymptomatic HH subjects was similar to that of age-sex matched normal volunteers at one cross-sectional time point. 3 Iron overload, which is induced by HH, has been shown to cause diastolic and systolic dysfunction, 4 and the long-term effect of HH on aerobic exercise capacity has not been reported, although this would be of interest to healthcare professionals. It is of special interest for those who monitor athletes with HH because a higher frequency of HFE (hemochromatosis gene) mutations that cause HH is reported among endurance runners. 5 In addition, the long-term effectiveness of conventional phlebotomy therapy in preventing HHassociated complications such as hypothyroidism, liver malignancy, arthritis, systolic and diastolic cardiac dysfunction, and cardiac arrhythmias is not well elucidated. 6Y8 Likewise, the long-term therapeutic benefit of conventional phlebotomy therapy on aerobic exercise capacity has not been reported. We had an opportunity to serially track the aerobic exercise capacity of cardiac asymptomatic subjects with HH, whose baseline observations were reported in this journal, under the National Heart, Lung, and Blood InstituteYsponsored BHeart Study of Hemochromatosis (NCT00068159)[ during a 5-yr span. Therefore, we now report on the changes in aerobic exercise capacity at 5-yr follow-up in HH subjects who received conventional phlebotomies during this period in comparison with volunteer control subjects.
METHODS

Study Subjects
The study was conducted at the clinical center of the National Institutes of Health. Forty-three subjects with HH and 21 age-and sex-matched healthy controls were initially recruited to participate in a National Heart, Lung, and Blood Institute institutional review boardYapproved protocol (03-H-0282 [NCT00068159]), between September 2003 and August 2005. All subjects provided written informed consent, and the protocol was consistent with the principles of the Declaration of Helsinki. 9 Eligibility criteria for study participation among HH subjects included the following: (1) 21 yrs or older, (2) asymptomatic, (3) genetic studies showing homozygosity for the C282Y HFE gene mutation, (4) documented evidence of iron overload with serum ferritin levels greater than 400 Kg/liter or transferrin saturation greater than 60%, and (5) absence of significant end-organ damage secondary to HH. Study eligibility for control subjects included the following: (1) 21 yrs or older, (2) New York Heart Association (NYHA) functional class I, (3) genetic studies showing the absence of C282Y or H63D mutations in the HFE gene, and (4) normal ferritin and transferrin saturation levels. All subjects with excessive alcohol ingestion, uncontrolled hypertension, diabetes requiring insulin or more than one oral hypoglycemic agent, tobacco use in the past 3 mos, and/or beta-adrenergic blocker or calcium channel blocker use were excluded from our study. Patients were recruited with the assistance of the National Institutes of Health Clinical Center Patient Recruitment and Public Liaison Office and via direct mailings of study information to physicians (BAPPENDIX[). All subjects were contacted for a fifth-year follow-up, and all HH subjects were treated under current therapeutic phlebotomy guidelines. 10, 11 Cardiopulmonary Exercise Testing Treadmill cardiopulmonary exercise testing was performed using the Bruce protocol. 12 Electrocardiography (ECG) tracings, clinical symptoms, blood pressure, and respiratory gas analysis were recorded continuously throughout the test. Workload was expressed as metabolic equivalents by dividing peak oxygen consumption (V O 2 ) (in milliliters of O 2 per kilogram per minute) by 3.5. Simultaneous respiratory gas analysis was performed using breathby-breath analysis of O 2 and CO 2 on a Carefusion Vmax Spectra 229c instrument (Carefusion, San Diego, CA). 3, 13, 14 The oxygen and carbon dioxide sensors were calibrated before each exercise test. The ventilatory sensor was likewise calibrated before each exercise test using a 3-liter syringe. Minute ventilation (V E), V O 2 , and carbon dioxide production (V CO 2 ) were measured. Peak V O 2 was defined as the highest 20-secYaveraged V O 2 achieved during exercise, and the peak respiratory exchange ratio, the ratio between V CO 2 and V O 2 , was also calculated from the same interval. Peak V O 2 was normalized to age and sex using the formula published by Jones et al. 15 Ventilatory threshold was determined using the Vslope analysis method. 16 The V E/V CO 2 slope, a parameter used to assess ventilatory efficiency during exercise, 17Y21 was calculated as previously described 19 because HH has been linked to cardiac dysfunction. 4 A V E/V CO 2 slope less than 30 is considered a normal response to exercise. 17Y19, 21, 22 Exercise ECG Response An abnormal ischemic exercise electrocardiogram was defined by a cardiologist (Y. Shizukuda) using conventional criteria of 1 mm or more of horizontal or downsloping ST-segment depression for at least 80 msecs after the end of QRS complex. 23 A complex arrhythmia was defined as ventricular couplets, ventricular tachycardia, or supraventricular tachycardia.
Statistical Analysis
Paired Student's t tests were used to compare measurements between HH and controls; however, the nonparametric Wilcoxon's rank-sum test was applied when normality of data could not be established. To compare baseline measurements with those at the fifth-year follow-up, a paired Student's t test was used. The effect of iron-depletion phlebotomy therapy was ascertained using paired Student's t tests. For categorical data, a W 2 test was used to compare measurements between baseline and the fifth-year follow-up and HH and control subjects at the same time point. Data are expressed as mean T standard deviation. A P value less than 0.05 was considered to be statistically significant. Data consistency was confirmed using a 2 Â 2 repeated measures analysis of variance design evaluating group Â time interaction when a statistical significance was detected. 
RESULTS
Baseline Characteristics
No subject was censored between baseline and the fifth-year follow-up evaluation. Nine HH and three control subjects were lost to follow-up, and one HH subject declined to have a follow-up cardiopulmonary exercise testing test. Among 33 HH subjects who completed the fifth-year follow-up, 19 were in the stable maintenance phase of phlebotomy therapy with steady iron levels, and 14 were subjects recently given diagnoses at baseline. 24 Both the HH and control groups contained a similar proportion of female subjects (33% vs. 32%, HH subjects vs. control subjects), and the details of the baseline characteristics have been published previously. 25 The mean age was comparable between the HH and control groups (51 T 10 vs. 50 T 8 yrs) at baseline. The average age of control dropouts was significantly younger than that of the entire control group (39 T 3 vs. 48 T 8 yrs, P G 0.01). Otherwise, the dropouts were comparable demographically with those in their respective study groups (data not shown). The HH subjects who completed fifth-year follow-up demonstrated significantly higher transferrin saturation at baseline and at the fifth-year follow-up compared with con-trols ( Table 1 ). Ferritin and aspartate aminotransferase decreased from baseline to the fifth-year follow-up in HH subjects.
Exercise Performance Parameters
Aerobic exercise performance, measured using exercise time, peak V O 2 , ventilatory threshold, heart rate and hemodynamic responses, did not differ significantly between HH and control subjects at the fifth-year follow-up (Table 2 ). In addition, the V E/ V CO 2 slope was comparable between the groups at the fifth-year follow-up (Table 2 ). Peak respiratory exchange ratio, the gold standard index of exercise effort, 21 was also comparable between the groups and indicated excellent exercise effort. At the fifthyear follow-up, peak respiratory exchange ratio slightly decreased from baseline in HH subjects, although the mean value was still consistent with maximal effort. On the other hand, peak V O 2 normalized to age and sex, and ventilatory threshold slightly increased in HH subjects at the fifth-year follow-up compared with baseline. These changes were not observed in control subjects ( Table 2 ).
Exercise ECG Responses at the Fifth-Year Follow-Up
The incidence of an abnormal ischemic ECG response at the fifth-year follow-up was no longer HH, hereditary hemochromatosis subjects with C282Y homozygous mutation; MET, metabolic equivalent; BP, blood pressure; RPP, rate pressure product; V E, minute ventilation; V CO 2 , respiratory CO 2 content; RER, respiratory exchange ratio. significant in asymptomatic HH subjects compared with control subjects (39% vs. 33% of subjects) in contrast with the baseline as we previously published. 3 Complex cardiac arrhythmias tended to occur more frequently in asymptomatic HH subjects (24% vs. 17% of subjects), but it did not reach statistical significance.
Effect of Phlebotomy on Exercise Performance for Newly Diagnosed HH Subjects
Fourteen newly diagnosed HH subjects at the time of recruitment completed repeat cardiopulmonary exercise testing after 5 yrs of phlebotomy therapy. As seen in the 6 month follow-up of this cohort in our previous report, 3 exercise capacity measured with exercise time, peak V O 2 , ventilatory threshold, and the V E/V CO 2 slope did not change significantly at the extended period of 5-yr treatment ( Fig. 1 ). In addition, the incidence of cardiac arrhythmias during exercise tended to decrease after 5 yrs of phlebotomy therapy in this group (50% vs. 21%, data are before and after phlebotomy therapy, P = 0.111). In addition, these main findings did not change if the 5-yr missing values were imputed with mean levels for the group (data not shown), and significant results were confirmed with a significant group Â time interaction by a 2 Â 2 repeatedmeasures analysis of variance (data not shown).
DISCUSSION
Our study at fifth-year follow-up demonstrates that (1) overall aerobic exercise capacity and venti-latory efficiency in cardiac asymptomatic HH subjects was not statistically different from that seen in healthy control subjects, (2) iron removal through 5 yrs of phlebotomy therapy did not affect aerobic exercise capacity compared with control subjects.
Iron overload caused by HH has been reported to cause both systolic and diastolic dysfunction in studies in which the average age was 50 to 53 yrs, and the average duration from diagnosis was 13 mos to 4 yrs. 26Y28 Once systolic dysfunction is documented, aerobic exercise capacity becomes compromised. 26, 27 We have previously demonstrated that cardiac asymptomatic HH subjects have a similar aerobic exercise capacity compared with apparently healthy control subjects. 3 However, it was not clear at that point whether this would be a consistent finding at long-term follow-up because we have found that these HH subjects continue to be exposed to elevated levels of oxidative stress even as iron levels are improved, 29 and oxidative stress may affect aerobic exercise capacity through modulation of the left ventricular diastolic function. 30 In addition, long-term follow-up data on aerobic exercise capacity in this population can be helpful in determining the effectiveness of current phlebotomy therapy regimens. Our study shows that overall aerobic exercise capacity continues to be comparable with normal subjects in asymptomatic HH subjects treated with chronic phlebotomy therapy at the fifth-year follow-up.
Although we speculated that an elevated iron level is detrimental to aerobic exercise capacity, there is a conflicting view suggesting the possible beneficial effect of increased iron on exercise performance. 5 We have previously reported that the lack of a significant association between iron levels and aerobic exercise capacity parameters suggests that iron levels are an unlikely determinant of functional performance. 3 Our follow-up results further support our previous observation.
The higher incidence of ischemic ECG changes were noted in HH subjects in our baseline evaluation, 3 and our previous report revealed that none of the asymptomatic subjects with ischemic ECG responses demonstrated abnormal left ventricular wall motion assessed through echocardiography during symptom-limited supine bicycle exercise. 3, 24 Furthermore, 50% of abnormal ST responses of HH subjects were transient, lasting less than 1 min. Our fifth-year follow-up data show that approximately one third of HH subjects have ST depression with exercise, but the incidence of ischemic ECG responses is no longer significantly higher in HH subjects. At the fifth-year follow-up, 43% of abnormal ST responses in HH subjects and 55 % of those in control subjects were transient, lasting less than 1 min. This may be partly explained by an increase in false-positive ECG changes during exercise in control subjects during the fifth-year follow-up, reaching a similar frequency as those in HH subjects at baseline.
Complex cardiac arrhythmias during exercise are not significantly different between HH and control subjects at the fifth-year follow-up. This may be partly related to a tendency of decreased cardiac arrhythmias generally in newly diagnosed HH subjects who were treated for 5 yrs through phlebotomy.
Limitations
Our study size was too small to allow comparisons of aerobic exercise capacity in different clinical subsets, such as male vs. female. In addition, it is possible that a larger study may detect slight differences in aerobic exercise capacity between HH and control subjects. Self-reported joint pain was more frequent in HH subjects compared with normal subjects at baseline, 3 and, although this was not assessed at the fifth-year follow-up, this might have affected exercise performance in HH subjects given that peak respiratory exchange ratio slightly decreased after 5 yrs in HH subjects. However, joint discomfort being the reason for exercise termination was infrequently reported by HH subjects and was comparable with control subjects at the fifthyear follow-up (9% in HH subjects, 6% in control subjects, P = 0.654). Our subjects' exercise habits were not matched between HH and control groups, and this might introduce bias into the results.
The sample number of this study is even smaller than our original publication investigating aerobic exercise capacity in asymptomatic HH subjects caused by attrition during the fifth-year follow-up, and it is possible that the associated hypotheses of interest were underpowered. It is also possible that the younger age of dropouts in control subjects could affect the main study conclusions. In addition, a statistical analysis of multiple variables can increase a chance of coincidental statistical significance.
In conclusion, our study shows that aerobic exercise capacity is comparable between cardiac asymptomatic HH subjects and healthy controls after the fifth-year follow-up. Further investigation is warranted to assess an even longer-term effect of HH on aerobic exercise capacity.
